


 Analyst: **Phibion Makuwerere, CFA**  
 Email: [pmakuwerere@Intellidex.co.za](mailto:pmakuwerere@Intellidex.co.za)

## The Company: Mediclinic International plc

### A sector in search of cure for regulatory pain

#### Our call

**Hold**

 Intellidex estimate of fair value: **R70.58**  
 Spot price: **R61.59**  
 Potential move: **14.6%**

#### Share price graph and Intellidex's previous calls



#### Background

Mediclinic International provides acute care, specialist-orientated and multi-disciplinary hospital and related services in three regions: Southern Africa, Switzerland and the United Arab Emirates (UAE). Its primary listing is in London, with secondary listings in SA and Namibia.

In Southern Africa it has more than 8,000 inpatient beds through 51 hospitals and three day-care clinics. Hirshlanden (Switzerland) has more than 1,800 inpatient beds and operates 17 private acute care facilities and four clinics; and Mediclinic Middle East operates seven hospitals and 22 clinics with more than 930 inpatient beds in the UAE. Mediclinic also has an associate stake in the UK-listed Spire Healthcare.

#### Sensitivity analysis: discounted cash-flow valuation

Terminal growth	2.0%	4.0%	6.0%
7.0%	11820	20381	63187
9.0%	6510	9644	16959
10.0%	4921	<b>7058</b>	11350
12.0%	2637	3726	5540
13.0%	1838	2654	3936

This reflects the sensitivity of our forecasts to assumptions of the terminal growth rate and the weighted average cost of capital (WACC). The highlighted cell shows our target price in cents.

#### Investment thesis

To understand the story of Mediclinic we begin by shedding light on how much each of its three segments contribute to group operations. Its biggest source of revenue is Switzerland, which contributed 45% of revenue and 42% of operating profit (down from 48%) before depreciation and amortisation (Ebitda) in 1H19 to end-September. This is followed by southern Africa which accounts for 32% of revenue and 44% (up from 40%) of Ebitda. Finally, UAE makes up 22% of group revenue and 14% (up from 12%) of Ebitda.

Since 2016 Mediclinic has battled with negative regulatory developments in all its operating geographies. At the moment most of the regulatory pain is emanating from Hirshlanden in Switzerland.

Patient outmigration in Hirshlanden is gathering pace, which saw the inpatient revenue per admission declining by 2.8% after dropping by 0.8% in the comparative period. (Outmigration occurs when ailments which used to be treated as inpatient conditions are reclassified as outpatient. Outpatient conditions

draw lower tariffs, thus lower margins. This development has seen Hirshlanden's Ebitda margin compressing to 14.3% from 17.4%. Given that it is the major revenue contributor, this has overshadowed margin gains in the UAE. Group Ebitda has fallen 8.2% to £214m. The market was not amused and the counter has been hammered. Between FY16 and 1H19 the Ebitda margin has fallen from 18.1% to 15.4%. The scary part is that more outmigration regulation is expected in 2019 and it is difficult to ascertain how much more damage it will inflict.

However, management is doing something about it. During 1H19 it identified and implemented some cost-saving initiatives, which will become more entrenched in 2H19. Furthermore, the customary Swiss seasonal benefits in the second half of the year typically generate higher patient volumes and an improved patient mix. As such Hirshlanden is expecting to deliver an Ebitda margin of around 16% for FY19 from 14.3% in 1H19 (FY18: 18.3%).

For the medium term, Hirshlanden is

adapting to the changing inpatient environment, making fundamental changes to its service model and cost structure, including areas such as supply costs, service differentiation, operational efficiency, doctor recruitment and hospital reconfiguration. It is also improving its outpatient delivery model – borrowing from its SA and UAE experiences – including the opening of outpatient surgery units, medical centres and doctors consulting rooms. It is reconfiguring theatres and recovery areas in existing hospitals to treat the growing volume of outpatient cases cost-effectively. Additionally, management is reducing Hirshlanden's capital allocation.

The group is taking advantage of the low interest environment by raising most of its funding in Switzerland, yet ringfencing it with its Swiss assets. This has reduced the cost of capital in our Mediclinic valuation model. Most top line growth is expected to come from the UAE – albeit off a low base – through the new Parkview hospital in Dubai that opened in September. Margins in the UAE are also expected to continue improving as capacity utilisation increases.

Southern Africa is expected to continue delivering modest growth in line with inflation.

We expect Mediclinic to experience average annual revenue and earnings growth of 4.1% and 10.5% respectively in the short to medium term. We see earnings gradually falling to a sustainable growth rate of 4.0% in the terminal year of our model. We assume that its adjusted pre-tax operating margin will stabilise at around 13.7%.

Using a discount rate of 10.0%, we obtain a target price of R70.58/share, which translates to upside potential of 14.6%. However, a price:earnings-to-growth (PEG) ratio of 1.5, based on our expectations of Mediclinic's short- to medium-term earnings growth rate, is bearish. (A PEG ratio of less than one indicates that growth is expected to be strong relative to the current price:earnings ratio). Since the PEG ratio is well above one, it reflects heightened downside risk in our price target. As such this is a hold even though the upside potential suggests a buy.

#### Analysis of results

Although revenue was up in all three operating currencies (rand, Swiss franc and dirham), the average exchange rate of the reporting currency (pound sterling) was stronger than all the operating currencies during 1H19. This saw the reported pound revenue edging lower. The Ebitda margin shrank to 15.4% from 16.5%, primarily as a result of regulatory headwinds in Switzerland.

During 1H19 the pound strengthened 4% against the rand and Swiss franc and 3% against the dirham. A 10% change in the average exchange rate during 1H19 would increase/decrease: Swiss profit by £3m (1H18: £5m); southern Africa profit by £4m (1H18: £5m); and UAE profit by £1m (1H18: £2m).

Hirshlanden (Swiss) revenue edged up 1% to CHF826m. Margins came under pressure due to draconian regulatory changes that have adversely affected the pricing of

services. Ebitda fell to 14.3% (17.4%). Southern Africa revenue grew 5% to R7.96bn. The Ebitda margin widened to 21.2% from 21%.

AUE revenue grew 5% to AED1.5bn. Its Ebitda margin rose to 9.4% from 8.8%, benefiting from increased capacity utilisation.

The group realised significant impairment charges which saw its operating profit tank by more than 70%, but headline earnings grew 23% a share since it excludes these non-frequent charges.

#### Macroeconomic analysis

Over the past few years hospitals have enjoyed premium valuations but recently these have come down sharply as earnings have consistently disappointed. We don't believe the high valuations were due to growth potential but rather to their defensive, non-cyclical properties: basic need status, ageing populations and a growing disease burden.

The two primary sources of organic growth for hospitals are patient volumes and price increases – with the latter under regulatory pressure, which is chipping away the sector's pricing power. A third dimension relates to expansion of services, but it is still tied to volume. Volume is directly related to population growth – which by nature is quite pedestrian. However, areas of potential volume growth include expansion of services/products and the growing demand for high-margin procedures as the middle class expands and the population's average age increases.

In SA, private healthcare providers have low market penetration of less than a fifth of the population. This presents huge growth potential but in the face of low economic growth, high unemployment and the possibility of national health insurance, the outlook is far from certain.



#### Bull Factors

- Reversal of draconian medical insurance in UAE
- New capacity added in UAE
- Pivoting towards higher-margin services and premium insurance patients in UAE
- Recent acquisition in Geneva should help stem revenue and margin decay
- Cost-containment initiatives
- Ageing population in Europe, Africa and Middle East is expanding and expenditure on health care is expected to catch global levels
- Geographical diversification reduces business risk
- LSE listing improves access to cheaper capital and share liquidity



#### Bear Factors

- Tight regulatory environment in Switzerland and SA to curb medical cost inflation
- Affordability might constrain growth, especially in Africa
- Currency impact difficult to predict

#### Key statistics

 Share details – JSE Code: **MEI**  
 Sector: **Healthcare providers**

Market cap: <b>R45.4bn</b>	12-month high: <b>R120.23</b>
Net debt:equity ratio: <b>54.5%</b>	12-month low: <b>R60.10</b>
Price:earnings ratio: <b>12.0</b>	Ave monthly volume: <b>24.3-million</b>
Forward PE ratio (FY19): <b>11.9</b>	Financial year-end: <b>31 March 2019</b>
Dividend yield: <b>2.2%</b>	Latest event: <b>Interim results</b>
Forward dividend yield: <b>2.23%</b>	Date announced: <b>15 November 2018</b>
Risk: <b>High</b>	

RESULTS IN BRIEF	1H19	Change	1H18	FY18
Revenue (£'m)	1 387.0	-1.3%	1 405.0	2 870.0
Operating profit (£'m)	39.0	-73.7%	133.0	-288.0
Operating margin (%)	2.8%	-70.3%	9.5%	-10.0%
Attributable earnings (£'m)	-168.0	236.0%	-50.0	-492.0
HEPS (pence)	10.7	23.0%	8.7	27.6

#### Intellidex Disclaimer:

This research report was issued by Intellidex (Pty) Ltd. Intellidex aims to deliver impartial and objective assessments of securities, companies or other subjects. This document is issued for information purposes only and is not an offer to purchase or sell investments or related financial instruments. Individuals should undertake their own analysis and/or seek professional advice based on their specific needs before purchasing or selling investments. The information contained in this report is based on sources that Intellidex believes to be reliable, but Intellidex makes no representations or warranties regarding the completeness, accuracy or reliability of any information, facts, estimates, forecasts or opinions contained in this document. The information, opinions, estimates, assumptions, target prices and forecasts could change at any time without prior notice. Intellidex is under no obligation to inform any recipient of this document of any such changes. Intellidex, its directors, officers, staff, agents or associates shall have no liability for any loss or damage of any nature arising from the use of this document.

#### Remuneration:

The opinions or recommendations contained in this report represent the true views of the analyst(s) responsible for preparing the report. The analyst's remuneration is not affected by the opinions or recommendations contained in this report, although his/her remuneration may be affected by the overall quality of their research, feedback from clients and the financial performance of Intellidex (Pty) Ltd. Intellidex staff may hold positions in financial instruments or derivatives thereof which are discussed in this document. Trades by staff are subject to Intellidex's code of conduct which can be obtained by emailing [mail@intellidex.co.za](mailto:mail@intellidex.co.za). Intellidex may also have, or be seeking to have, a consulting or other professional relationship with the companies mentioned in this report.

#### Guide to recommendations:

A buy recommendation is made where the target price is 10% above the current price, a sell when it is 10% below the current price, and a hold recommendation when it is within 10% of the current price. The risk measure is a subjective determination guided by the beta of the share price. We also examine the financial and operating leverage of the business. ©This document is copyrighted by Intellidex (save for information contained in this document provided by third parties which may be copyrighted to them) and may not be distributed in any form without the express prior written permission of Intellidex.

#### Absa Stockbrokers and Portfolio Managers Disclaimer:

This research note is prepared for Absa Stockbrokers and Portfolio Managers (Pty) Ltd ("SPM") by Intellidex (Pty) Ltd, a company registered in South Africa, registration number: 2008/005881/07 ("Intellidex"). Intellidex is an independent company contracted to Absa. The views expressed in this note are those of Intellidex and/or its analysts and are not necessarily the views of SPM or any officer or agent thereof. The information contained in this communication does not constitute an offer or the solicitation of an offer to enter into any transaction for the sale or purchase of any security, nor does it constitute any recommendation, guidance or proposal to enter into any transaction for the sale or purchase of any security. The information is provided for illustrative purposes only and is not guaranteed. SPM does not represent or warrant that the information contained in this report is true or accurate and no undertaking (express or implied) is given and no responsibility nor liability is accepted by any member of SPM, its employees and agents, or any other person or company affiliated to SPM, as to the accuracy of the information contained herein. Past performance is no indication of future performance. SPM does not accept any liability or responsibility for any loss, damage or expense incurred in relying on the above information or in the use thereof, nor makes any representation as to the accuracy or completeness of the above information. All opinions, estimates and findings contained in this document may be changed after distribution by Intellidex at any time without notice.

This document has been prepared in accordance with local regulations which may differ from the requirements in other jurisdictions. In distributing this research to you, SPM does not hold this out to be impartial (objective) as it may have been prepared by persons who may be exposed to conflicts of interest.

You should be aware that this document might have been originally disseminated by Intellidex to its clients other than SPM. As such, employees and clients of Intellidex and any persons connected with it may have had the opportunity to act upon the information contained in this document. The recipients of this document are urged to seek independent advice with regard to the securities and investments referred to in this document.

#### FAIS Notice and Disclaimer:

This brochure/document/material/report/communication/commentary ("this commentary") has been prepared by Absa Stockbrokers and Portfolio Management ("SPM"). SPM has issued this commentary for information purposes only and you must not regard this as a prospectus for any security or financial product or transaction. We do not expressly, tacitly or by implication represent, recommend or propose that the securities and/or financial or investment products or services (the "Products") referred to in this commentary are appropriate and/or suitable for your particular investment objectives or financial situation and/or needs. This commentary is not, nor is it intended to be, advice as defined and/or contemplated in Financial Advisory and Intermediary Services Act, 37 of 2002 ("FAIS"), or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever ("advice"). All the risks and significant issues related to or associated with the Products are not disclosed herein and therefore, prior to investing or transacting, you should fully understand the Products and any risks and significant issues related to or associated with them. This commentary is neither an offer to sell nor a solicitation of an offer to buy any of the Products, which shall always be subject to our internal approvals and the execution of all requisite documentation. You have to obtain your own advice prior to making any decision or taking any action based hereon and we, our affiliates, officers, directors, partners, or employees (in whose favour this constitutes a stipulation on behalf of another) do not accept any liability whatsoever for any direct, indirect or consequential damages or loss arising from any use of or reliance on this publication or its contents, and irrespective of whether or not you have obtained independent advice. Should you be a consumer in terms of the Consumer Protection Act No 68 of 2008, as amended, (i.e. a natural person or an entity with an asset value and annual turnover below R2m), then the above provisions limit and exclude the liabilities which we will have towards you and also place obligations on you.

Absa Stockbrokers and Portfolio Management (Pty) Limited is a member of the JSE Equity Market, Registered Credit Provider Reg. No. NCRCP68, and an Authorised Financial Services Provider with FSP No 45849. Absa Stockbrokers and Portfolio Management (Pty) Ltd is a wholly owned subsidiary of Absa Group Ltd ("Absa") and complies with Absa's privacy and security policies. However, business is conducted directly with Absa Stockbrokers and Portfolio Management (Pty) Ltd.